PharmaShots | Incisive News in 3 Shots

Subscribe Now

Intas

Intas and Dong-A ST Report EMA Acceptance of MAA for DMB-3115, a Proposed Biosimilar to Stelara (ustekinumab)

Intas and Dong-A ST Report EMA Acceptance of MAA for DMB-3115, a Proposed Biosimilar to Stelara (ustekinumab)

July 17, 2023

Intas Entered into an Exclusive License Agreement with Syna to Commercialize Biosimilar LB-0702

Intas Entered into an Exclusive License Agreement with Syna to Commercialize Biosimilar LB-0702

November 3, 2022

Insights+ Key Biosimilars Events of April 2022

Insights+ Key Biosimilars Events of April 2022

May 5, 2022

Intas Signs an Exclusive License & Supply Agreement with Axantia for Ranibizumab Biosimilar to Treat Eye Disorders

Intas Signs an Exclusive License & Supply Agreement with Axantia for Ranibizumab Biosimilar to Treat Eye Disorders

April 4, 2022

Insights+ Key Biosimilars Events of July 2021

Insights+ Key Biosimilars Events of July 2021

August 5, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us